PAP + HPV Co-Testing Increases Cevical Cancer Detection

Article

Recent developments in cervical cancer screening, including the approval of a DNA-based HPV test as a stand-alone method for screening, has stirred debate on whether the Pap test should remain part of frontline cervical cancer screening.

 

PAP + HPV Co-Testing Increases Cevical Cancer Detection



Historically, the Papanicolaou (Pap) test was one of the most powerful weapons primarily responsible for the dramatic reduction in cervical cancer in the twentieth century. By the beginning of the twenty-first century, the combined use of Pap tests and high-risk human papillomavirus virus (HPV) based molecular assays contributed to a steady decline in the incidence of cervical cancer. However, recent developments in cervical cancer screening, including the approval of a DNA-based HPV test as a stand-alone method for screening, has stirred debate on whether the Pap test should remain part of frontline cervical cancer screening.

 

 

Related Videos
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Unlocking the benefits of DHEA | Image Credit: drannacabeca.com
Unlocking the power of oxytocin | Image credit: drannacabeca.com
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Deciding the best treatment for uterine fibroids | Image Credit: jeffersonhealth.org.
Clinical pearls of pediatric dermatology | Image Credit: profiles.ucsf.edu
Approaching inflammatory vulvovaginal diseases | Image Credit: profiles.ucsf.edu.
© 2024 MJH Life Sciences

All rights reserved.